DRUGS & SUPPLEMENTS

Trixilem

advertisement
How old is patient?

Trixilem uses


WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY

Trixilem can cause the following severe or fatal adverse reactions.

Monitor closely and modify dose or discontinue Trixilem as appropriate.

  • Bone marrow suppression
  • Serious infections
  • Renal toxicity and increased toxicity with renal impairment
  • Gastrointestinal toxicity
  • Hepatic toxicity
  • Pulmonary toxicity
  • Hypersensitivity and dermatologic reactions
  • Trixilem can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of Trixilem and risks to the fetus when prescribing Trixilem to a pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use effective contraception during and after treatment with Trixilem .

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning.

  • Trixilem can cause severe or fatal toxicities. Monitor closely and modify dose or discontinue for the following toxicities: bone marrow suppression (5.1), infection (5.2), renal (5.3), gastrointestinal (5.4), hepatic (5.5), pulmonary (5.6), hypersensitivity and dermatologic (5.7).
  • Trixilem can cause embryo-fetal toxicity and fetal death. Use in polyarticular juvenile idiopathic arthritis is contraindicated in pregnancy (4). Consider the benefits and risks of Trixilem and risks to the fetus when prescribing Trixilem to a pregnant patient with a neoplastic disease. Advise patients to use effective contraception during and after treatment with Trixilem (5.9, 8.1, 8.3).
advertisement

1 INDICATIONS AND USAGE

Trixilem is a folate analog metabolic inhibitor indicated for the:

  • Treatment of pediatric patients with acute lymphoblastic leukemia as a component of a combination chemotherapy maintenance regimen (1.1)
  • Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy (1.2)

1.1 Acute Lymphoblastic Leukemia

Trixilem is indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen.

1.2 Polyarticular Juvenile Idiopathic Arthritis

Trixilem is indicated in the management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

2 DOSAGE AND ADMINISTRATION

  • Use another formulation of Trixilem for patients requiring dosing via routes of administration other than oral.
  • Measure with an accurate measuring device (2.1).

Recommended

Dosage:

  • ALL: 20 mg/m2 one time weekly (2.2)
  • pJIA: Starting dose of 10 mg/m2 one time weekly (2.3)

2.1 Important Administration Information

Trixilem is intended for oral use only. Use another formulation of Trixilem for alternative dosing in patients who require dosing via other routes of administration. Instruct patients and caregivers that the recommended dose should be taken weekly, as directed, and that mistaken daily use of the recommended dose has led to fatal toxicity .

It is important that Trixilem be measured with an accurate measuring device . A household teaspoon is not an accurate measuring device. A pharmacist can provide an appropriate device and can provide instructions for measuring the correct dose.

2.2 Acute Lymphoblastic Leukemia

The recommended starting dose of Trixilem, in multi-agent combination chemotherapy maintenance regimens, is 20 mg/m2 given one time weekly. After initiating Trixilem, continuation of appropriate dosing requires periodic monitoring of absolute neutrophil count and platelet count to assure sufficient drug exposure (that is to maintain ANC at a desirable level) and to adjust for excessive hematological toxicity.

2.3 Polyarticular Juvenile Idiopathic Arthritis

The recommended starting dose of Trixilem is 10 mg/m2 given one time weekly.

Dosages should be tailored to the individual patient and adjusted gradually to achieve an optimal response. Although there is experience with doses up to 30 mg/m2/week in pediatric patients, doses greater than 20 mg/m2/week may result in a significant increase in the incidence and severity of serious toxic reactions, especially bone marrow suppression. Doses between 20 and 30 mg/m2/week (0.65 to 1 mg/kg/week) may have better absorption and fewer gastrointestinal side effects if Trixilem is administered by an alternative route using another formulation.

Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more.

Certain side effects such as mouth sores may be reduced by folate supplementation with Trixilem in pJIA.

2.4 Evaluations Prior to Starting Trixilem

Assess hematologic, hepatic, and renal function before beginning, as well as periodically during and before reinstituting, therapy with Trixilem . Exclude pregnancy in females of reproductive potential before starting Trixilem .

2.5 Handling Information

Trixilem is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

advertisement

3 DOSAGE FORMS AND STRENGTHS

Trixilem is a clear yellow to orange oral solution that contains 2.5 mg of Trixilem per milliliter.

Oral solution: 2.5 mg/mL (3)

4 CONTRAINDICATIONS

Trixilem is contraindicated in the following:

  • Pregnancy in patients with non-malignant diseases. Trixilem can cause embryo-fetal toxicity and fetal death when administered during pregnancy .
  • Patients with severe hypersensitivity to Trixilem .
  • Pregnancy (patients with pJIA) (4)
  • Severe hypersensitivity to Trixilem (4)

5 WARNINGS AND PRECAUTIONS

  • Secondary malignancies can occur. In case of immunosuppression-associated lymphoma, discontinue Trixilem before starting treatment for lymphoma.
  • Immunizations may be ineffective (5.10).
  • Effects on reproduction: May cause impairment of fertility, oligospermia and menstrual dysfunction (5.11, 8.3).

5.1 Bone Marrow Suppression

Trixilem suppresses hematopoiesis and can cause severe and life-threatening pancytopenia, anemia, leukopenia, neutropenia, and thrombocytopenia.

Obtain blood counts at baseline and periodically during treatment. Monitor patients for possible clinical complications of bone marrow suppression. Provide supportive care and modify dose or discontinue Trixilem as needed.

5.2 Serious Infections

Patients treated with Trixilem are at increased risk for developing life-threatening or fatal bacterial, fungal, or viral infections including opportunistic infections such as Pneumocystis jiroveci pneumonia, invasive fungal infections, hepatitis B reactivation, tuberculosis primary infection or reactivation, and disseminated Herpes zoster and cytomegalovirus infections.

Monitor patients for the signs and symptoms of infection during and after treatment with Trixilem and treat promptly. Consider dose modification or discontinuation of Trixilem in patients who develop serious infections .

5.3 Renal Toxicity and Increased Toxicity with Renal Impairment

Trixilem can cause renal damage including acute renal failure. Monitor renal function to decrease the risk of renal injury and mitigate renal toxicity.

Consider administration of glucarpidase in patients with toxic plasma Trixilem concentrations (> 1 micromole per liter) and delayed clearance due to impaired renal function .

5.4 Gastrointestinal Toxicity

Trixilem can cause diarrhea, vomiting, stomatitis, hemorrhagic enteritis, and fatal intestinal perforation. Patients with peptic ulcer disease or ulcerative colitis are at a greater risk of developing severe gastrointestinal adverse reactions.

Interrupt or discontinue Trixilem and institute appropriate supportive care as needed.

Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of Trixilem and nonsteroidal anti-inflammatory drugs (NSAIDs) .

5.5 Hepatic Toxicity

Trixilem can cause severe and potentially irreversible hepatotoxicity including fibrosis, cirrhosis, and fatal liver failure. Avoid use of Trixilem in patients with chronic liver disease.

Assess liver function prior to initiating Trixilem and monitor liver function tests during treatment. Interrupt or discontinue Trixilem as appropriate. Transient asymptomatic acute liver enzyme elevations are common and are not predictive of subsequent hepatic disease. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis.

Other risk factors for hepatotoxicity include alcoholism, obesity, diabetes, hyperlipidemia, previous significant exposure to liver toxins, history of liver disease, family history of inheritable liver disease, persistent abnormal liver chemistry findings, duration of therapy, and advanced age.

5.6 Pulmonary Toxicity

Methotrexate-induced pulmonary toxicity including acute or chronic interstitial pneumonitis and irreversible or fatal cases can occur at all dose levels. Monitor patients for signs of pulmonary toxicity and interrupt or discontinue Trixilem as appropriate.

5.7 Hypersensitivity and Dermatologic Reactions

Severe, including fatal, dermatologic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, erythema multiforme, can occur with Trixilem. Discontinue Trixilem if severe dermatologic reactions occur.

Anaphylaxis can occur with Trixilem. If anaphylaxis or any other serious hypersensitivity reaction occurs, immediately discontinue Trixilem and institute appropriate therapy. Trixilem is contraindicated for use in patients with a history of severe hypersensitivity.

Radiation dermatitis and sunburn may be “recalled” by the use of Trixilem.

5.8 Secondary Malignancies

Secondary malignancies can occur at all dose levels of Trixilem.

There have been instances of lymphoproliferative disease associated with low-dose oral Trixilem which have regressed completely following withdrawal of Trixilem without institution of antineoplastic therapy. Discontinue Trixilem first and institute appropriate treatment if the lymphoma does not regress.

5.9 Embryo-Fetal Toxicity

Based on published reports and methotrexate’s mechanism of action, Trixilem can cause embryo-fetal toxicity and fetal death when administered to a pregnant woman. In pregnant women with non-malignant diseases, Trixilem is contraindicated. Consider the benefits and risks of Trixilem and risks to the fetus when prescribing Trixilem to a pregnant patient with a neoplastic disease. Advise females of reproductive potential to use effective contraception during therapy and for 6 months after the final dose. Advise males of reproductive potential to use effective contraception during and for at least 3 months after the final Trixilem dose .

5.10 Ineffective Immunization and Risks Associated with Live Vaccines

Immunization may be ineffective when given during Trixilem therapy.

Immunization with live virus vaccines is not recommended. There have been reports of disseminated vaccinia infections after smallpox immunization in patients receiving Trixilem therapy.

5.11 Effects on Reproduction

Based on published reports, Trixilem can cause impairment of fertility, oligospermia, and menstrual dysfunction. It is not known if the infertility is reversible in affected patients. Discuss the risk of effects on reproduction with female and male patients .

5.12 Increased Toxicity Due to ThirdSpace Accumulation

Trixilem can exit slowly from third‑space accumulations resulting in prolonged terminal plasma half-life and toxicity. Evacuate significant third-space accumulations prior to Trixilem administration .

5.13 Soft Tissue and Bone Toxicity with Radiation Therapy

Concomitant radiation therapy increases the risk of soft tissue necrosis and osteonecrosis associated with Trixilem.

5.14 Laboratory Tests

Closely monitor patients undergoing Trixilem therapy so that toxic effects are detected promptly. In general, monitoring of the following parameters is recommended: hematology at least monthly, renal function and liver function every 1 to 2 months [see Warnings and Precautions ].

Increase monitoring frequency during initial dosing, dose changes, or during periods of increased risk of elevated Trixilem blood levels (e.g., dehydration).

Liver Function Tests

Transient liver function test abnormalities are observed frequently after Trixilem administration and are usually not cause for modification of Trixilem therapy. Persistent liver function test abnormalities, and/or depression of serum albumin may be indicators of serious liver toxicity and require evaluation .

Pulmonary Function Tests

Pulmonary function tests may be useful if methotrexate-induced lung disease is suspected, especially if baseline measurements are available .

5.15 Risk of Improper Dosing

Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken one time weekly, as directed, and that mistaken daily use of the recommended dose has led to fatal toxicity .

Advise patients to measure Trixilem with an accurate milliliter measuring device. Inform patients that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions . Advise patients to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose .

advertisement

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling.

  • Bone Marrow Suppression
  • Serious Infections
  • Renal Toxicity and Increased Toxicity with Renal Impairment
  • Gastrointestinal Toxicity
  • Hepatic Toxicity
  • Pulmonary Toxicity
  • Hypersensitivity and Dermatologic Reactions
  • Secondary Malignancies
  • Ineffective Immunization and Risks Associated with Live Vaccines
  • Infertility
  • Increased Toxicity Due to Third‑Space Accumulation
  • Soft Tissue and Bone Toxicity with Radiation Therapy

Most common adverse reactions are: ulcerative stomatitis, leukopenia, nausea, abdominal distress, and elevated liver function tests. Other frequently reported adverse reactions are malaise, fatigue, chills and fever, dizziness and decreased resistance to infection (6).

To report SUSPECTED ADVERSE REACTIONS, contact Silvergate Pharmaceuticals at 1-855-379-0383 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.

The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, and abdominal distress. Other frequently reported adverse reactions are malaise, fatigue, chills, fever, dizziness, and decreased resistance to infection. Folate deficiency states may increase Trixilem toxicity.

Polyarticular Juvenile Idiopathic Arthritis

The approximate incidences of adverse reactions reported in pediatric patients with JIA treated with oral, weekly doses of Trixilem (5 to 20 mg/m2/week or 0.1 to 0.65 mg/kg/week) were as follows (virtually all patients were receiving concomitant nonsteroidal anti-inflammatory drugs, and some also were taking low doses of corticosteroids): elevated liver function tests, 14%; gastrointestinal reactions (e.g., nausea, vomiting, diarrhea), 11%; stomatitis, 2%; leukopenia, 2%; headache, 1.2%; alopecia, 0.5%; dizziness, 0.2%; and rash, 0.2%. Although there is experience with dosing up to 30 mg/m2/week in JIA, the published data for doses above 20 mg/m2/week are too limited to provide reliable estimates of adverse reaction rates.

6.2 Postmarketing Experience

Additional adverse reactions which have been identified during postmarketing use of Trixilem are listed below by organ system.

Blood and Lymphatic System Disorders: Suppressed hematopoiesis causing anemia, aplastic anemia, pancytopenia, leukopenia, neutropenia, thrombocytopenia, lymphaden-opathy, lymphoproliferative disorders (including reversible), hypogammaglobulinemia

Cardiovascular: Thromboembolic events (including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis, and pulmonary embolus), pericarditis, pericardial effusion, hypotension

Eye Disorders: Optic neuropathy, transient blindness, blurred vision, ocular irritation, conjunctivitis, xerophthalmia

Gastrointestinal Disorders: Gingivitis, pharyngitis, stomatitis, anorexia, nausea, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, enteritis, pancreatitis

Hepatobiliary Disorders: Hepatotoxicity, acute hepatitis, chronic fibrosis and cirrhosis, decreased serum albumin, liver enzyme elevations

Immune System Disorders: Vasculitis, lymphomas, and anaphylactoid reactions

Infections: Fatal opportunistic infections (most commonly Pneumocystis jiroveci pneumonia). There have also been reports of other infections, pneumonia, sepsis, nocardiosis, histoplasmosis, cryptococcosis, Herpes zoster, Herpes simplex hepatitis, and disseminated Herpes simplex

Metabolism: Hyperglycemia and tumor lysis syndrome

Musculoskeletal System: Stress fracture, soft tissue necrosis, osteonecrosis, arthralgia, myalgia, osteoporosis

Nervous System Disorders: Headaches, drowsiness, blurred vision, transient blindness, speech impairment (including dysarthria and aphasia), hemiparesis, paresis and convulsions have also occurred following administration of Trixilem.

Following low doses, there have been reports of transient subtle cognitive dysfunction, mood alteration, unusual cranial sensations, leukoencephalopathy, or encephalopathy.

Renal Disorders: Azotemia, hematuria, proteinuria, cystitis

Reproductive Disorders: Defective oogenesis or spermatogenesis, menstrual dysfunction, loss of libido, impotence, vaginal discharge, gynecomastia

Respiratory Disorders: Pulmonary fibrosis, respiratory failure, chronic interstitial obstructive pulmonary disease, pleuritic pain and thickening alveolitis

Skin Disorders: Erythematous rashes, pruritus, urticaria, photosensitivity, pigmentary changes, alopecia, ecchymosis, telangiectasia, acne, furunculosis, erythema multiforme, toxic epidermal necrolysis, Stevens‑Johnson syndrome, skin necrosis, skin ulceration, accelerated nodulosis, and exfoliative dermatitis.

advertisement

7 DRUG INTERACTIONS

  • Oral Antibiotics: May increase hematologic and gastrointestinal toxicity. Monitor patients accordingly.
  • Hepatotoxins: May increase risk of hepatotoxicity. Monitor patients accordingly (7.1).
  • Probenecid: May increase Trixilem exposure. Consider alternative drugs (7.1).
  • Theophylline: May reduce theophylline clearance. Monitor theophylline levels (7.2).

7.1 Effect of Other Drugs on Trixilem

Oral Antibiotics

Penicillins may reduce the renal clearance of Trixilem; increased serum concentrations of Trixilem with concomitant hematologic and gastrointestinal toxicity have been observed with Trixilem. Monitor patients accordingly .

Trimethoprim/sulfamethoxazole has been reported to increase bone marrow suppression in patients receiving Trixilem. Monitor patients accordingly .

Hepatotoxins

The potential for increased hepatotoxicity when Trixilem is administered with other hepatotoxic agents has not been evaluated; however, hepatotoxicity has been reported in such cases. Monitor patients receiving Trixilem with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity.

Probenecid

Probenecid may reduce renal elimination of Trixilem. Consider alternative drugs.

7.2 Effect of Trixilem on Other Drugs

Theophylline

Trixilem may decrease the clearance of theophylline. Monitor theophylline levels when coadministered with Trixilem.

8 USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed.

8.1 Pregnancy

Risk Summary

Based on published reports and methotrexate’s mechanism of action, Trixilem is a teratogen that can cause embryo-fetal toxicity and fetal death when administered to a pregnant woman . In pregnant women with non-malignant disease, Trixilem is contraindicated. Consider the benefits and risks of Trixilem and risks to the fetus when prescribing Trixilem to a pregnant patient with a neoplastic disease. There are no animal data that meet current standards for nonclinical developmental toxicity studies.

The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

Published data from cases, literature reviews, and observational studies report that Trixilem exposure during pregnancy is associated with an increased risk of embryo-fetal toxicity and fetal death. Trixilem exposure during the first trimester of pregnancy is associated with an increased incidence of spontaneous abortions and multiple adverse developmental outcomes, including skull anomalies, facial dysmorphism, central nervous system abnormalities, limb abnormalities, and sometimes cardiac anomalies and intellectual impairment. Adverse outcomes associated with exposure during second and third trimesters of pregnancy include intrauterine growth restriction and functional abnormalities. Because Trixilem is widely distributed and persists in the body for a prolonged period, there is a potential risk to the fetus from preconception Trixilem exposure.

A prospective multicenter study by U.S. and European teratology information services evaluated pregnancy outcomes in women taking Trixilem less than or equal to 30 mg/week after conception. The rate of spontaneous abortion/miscarriage in pregnant women exposed to Trixilem was 42.5% (95% confidence interval [95% CI] 29.2-58.7), which was higher than in unexposed autoimmune disease comparators (22.5%, 95% CI 16.8-29.7) and unexposed nonautoimmune disease comparators (17.3%, 95% CI 13-22.8). Of the live births, the rate of major birth defects in pregnant women exposed to Trixilem after conception was higher than in autoimmune disease comparators (adjusted odds ratio (OR) 1.8 [95% CI 0.6-5.7]) and nonautoimmune disease comparators (adjusted OR 3.1 [95% CI 1.03-9.5]). Major birth defects associated with pregnancies exposed to Trixilem after conception were not always consistent with methotrexate-associated adverse developmental outcomes.

8.2 Lactation

Risk Summary

Limited published literature report the presence of Trixilem in human milk in low amounts. The highest breast milk to plasma concentration ratio demonstrated was 0.08:1. No information is available on the effects of Trixilem on a breastfed infant or on milk production. Because of the potential for serious adverse reactions, including myelosuppression, from Trixilem in breastfed infants, advise women not to breastfeed during Trixilem therapy.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing

Test for pregnancy prior to initiating therapy with Trixilem.

Contraception

Females

Trixilem can cause fetal harm when administered to a pregnant woman .

Advise females of reproductive potential to use effective contraception during and for 6 months after the final Trixilem dose.

Males

Trixilem can cause chromosomal damage to sperm cells. Advise males with female partners of reproductive potential to use effective contraception during and for at least 3 months after the final Trixilem dose.

Infertility

Females

Based on published reports of female infertility after therapy with Trixilem, advise females of reproductive potential that Trixilem can cause impairment of fertility and menstrual dysfunction during and after cessation of therapy. It is not known if the infertility may be reversed in all affected females.

Males

Based on published reports of male infertility after therapy with Trixilem, advise males of reproductive potential that Trixilem can cause oligospermia or infertility during and after cessation of therapy. It is not known if the infertility may be reversed in all affected males.

8.4 Pediatric Use

Safety and effectiveness of Trixilem in pediatric patients have been established for the treatment of pediatric patients with acute lymphoblastic leukemia as part of a multi-phase, combination chemotherapy maintenance regimen and for the management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) .

8.6 Renal Impairment

Trixilem elimination is reduced in patients with impaired renal function. Monitor patients with renal impairment for an extended period of time. Consider a dose reduction or, in some cases, discontinue Trixilem administration .

8.7 Hepatic Impairment

The effect of hepatic impairment on Trixilem pharmacokinetics has not been studied. Patients with hepatic impairment may be more susceptible to hepatotoxicity . Consider dose adjustments or alternative treatments in patients with baseline hepatic impairment.

10 OVERDOSAGE

Manifestations

Fatal overdosage has occurred with Trixilem. Manifestations of overdosage include adverse reactions reported at pharmacologic doses, particularly hematologic and gastrointestinal reactions (e.g., leukopenia, thrombocytopenia, anemia, pancytopenia, bone marrow suppression, mucositis, stomatitis, oral ulceration, nausea, vomiting, gastrointestinal ulceration, or gastrointestinal bleeding). In some cases, no symptoms were reported.

Management

Leucovorin and levoleucovorin are indicated to diminish the toxicity and counteract the effect of inadvertently administered overdosages of Trixilem. Administer leucovorin or levoleucovorin as soon as possible after overdosage (refer to the leucovorin or levoleucovorin Prescribing Information). Monitor serum Trixilem concentrations closely to guide leucovorin or levoleucovorin therapy. Monitor serum creatinine concentrations closely because high serum Trixilem concentrations may cause renal damage leading to acute renal failure.

Glucarpidase is indicated for the treatment of toxic Trixilem concentrations in patients with delayed Trixilem clearance due to impaired renal function (refer to the glucarpidase prescribing information). If glucarpidase is used, do not administer leucovorin within 2 hours before or after a dose of glucarpidase because leucovorin is a substrate for glucarpidase.

In cases of massive overdosage, hydration and urinary alkalinization may be necessary to prevent the precipitation of Trixilem and/or its metabolites in the renal tubules. Neither hemodialysis nor peritoneal dialysis has been shown to improve Trixilem elimination. However, effective clearance of Trixilem has been reported with acute, intermittent hemodialysis using a high-flux dialyzer.

11 DESCRIPTION

Trixilem contains Trixilem, a folate analog metabolic inhibitor.

Chemically Trixilem is N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]-benzoyl]-L-glutamic acid. The structural formula is:

NDC 52652-2001-1

Trixilem

(methotrexate)

Oral Solution

2.5 mg/mL

For Oral Use Only

READY TO USE

120 mL

Silvergate

Pharmaceuticals Inc.

Rx Only

Each 1 mL contains 2.5 mg

Trixilem (equivalent to

2.74 mg Trixilem sodium).

Usual Dose:

See prescribing information.

Store refrigerated

2° - 8°C (36° - 46°F).

After dispensing, may be

stored at room temperature

15° - 30°C (59° - 86°F)

for 60 days.

KEEP THIS AND ALL

MEDICATIONS OUT OF THE

REACH OF CHILDREN

Manufactured for:

Silvergate Pharmaceuticals, Inc.

Greenwood Village, CO 80111

Lot:

EXp:

Trixilem pharmaceutical active ingredients containing related brand and generic drugs:

infoActive ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Trixilem available forms, composition, doses:

infoForm of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Trixilem destination | category:

infoDestination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Trixilem Anatomical Therapeutic Chemical codes:

infoA medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Trixilem pharmaceutical companies:

infoPharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."XATMEP (METHOTREXATE) SOLUTION [SILVERGATE PHARMACEUTICALS, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. Dailymed."METHOTREXATE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  3. "methotrexate". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Trixilem?

Depending on the reaction of the Trixilem after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Trixilem not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Trixilem addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sDrugs.com conducted a study on Trixilem, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Trixilem consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

One visitor reported frequency of use

How often in a day do you take the medicine?
Are you taking the Trixilem drug as prescribed by the doctor?

Few medications can be taken Twice in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sDrugs.com website users about the frequency of taking the drug Trixilem is mentioned below.
Visitors%
Twice in a day1
100.0%

One visitor reported doses

What is the dose of Trixilem drug you are taking?
According to the survey conducted among sDrugs.com website users, the maximum number of people are using the following dose 1-5mg. Few medications come in only one or two doses. Few are specific for adult dose and child dose. The dose of the medicine given to the patient depends on the severity of the symptom/disease. There can be dose adjustments made by the doctor, based on the progression of the disease. Follow-up is important.
Visitors%
1-5mg1
100.0%

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2019 "sDrugs.com". All Rights Reserved